Charles River Laboratories International, Inc. (CRL) entered into a lentiviral vector contract development and manufacturing organization (CDMO) agreement with Gates Institute. Per the terms of the deal, Gates Institute will utilize Charles River’s cutting-edge cell and gene therapy CDMO to develop chimeric antigen receptor (CAR) T-cell therapies for hematological cancers.The deal underscores the Gates Institute's mission to provide advanced solutions for cell and gene therapy.With this strategic agreement, ...